John Litchfield, DO
Gastroenterology · Charleston, SCNPI 1730329533
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 65.0% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2019 at $15,296 and has fallen 88.6% since, to $1,741 in 2025. Among gastroenterology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 545 payments — averaging $42.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$15K
- AbbVie$3K
- Johnson & Johnson$871
- Gilead$430
- Pfizer$382
- QOL Medical, LLC$357
- plus $4K from 32 others
What the payments were for
- Consulting fees$150%
- Speaking & faculty fees$11,60050%
- Travel & lodging$2,32910%
- Food & beverage$9,42740%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 78 | $15,224 |
| AbbVie(2 entities) | 166 | $2,619 |
| Johnson & Johnson | 52 | $871 |
| Gilead | 24 | $430 |
| Pfizer | 23 | $382 |
| QOL Medical, LLC | 22 | $357 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $347 |
| Sanofi | 15 | $342 |
| Ardelyx, Inc. | 14 | $300 |
| Evoke Pharma, Inc. | 6 | $264 |
| Bristol Myers Squibb | 16 | $257 |
| Intercept Pharmaceuticals, Inc. | 12 | $195 |
| Ironwood Pharmaceuticals, Inc | 10 | $155 |
| Phathom Pharmaceuticals, Inc. | 10 | $151 |
| Madrigal Pharmaceuticals | 8 | $144 |
| Organon | 5 | $142 |
| Alnylam Pharmaceuticals Inc. | 6 | $132 |
| Regeneron Healthcare Solutions, Inc. | 5 | $117 |
| Amgen | 7 | $113 |
| Lilly USA, LLC | 6 | $111 |
| Celltrion USA Inc. | 5 | $91 |
| Medtronic(2 entities) | 2 | $81 |
| Ferring Pharmaceuticals Inc. | 3 | $78 |
| Daiichi Sankyo Inc. | 4 | $77 |
| Nestle Healthcare Nutrition Inc. | 3 | $66 |
| Shire North American Group Inc | 3 | $60 |
| Braintree Laboratories, Inc. | 4 | $55 |
| Axonics, Inc. | 3 | $48 |
| Vivus LLC | 3 | $44 |
| Shionogi Inc | 2 | $32 |
| Boston Scientific | 2 | $23 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
| Merck | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Lucid Diagnostics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,417 in reported general payments places this provider in the 90th percentile of 259 gastroenterology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 52 | $40,422 |
| TrulancePlecanatide | 25 | $21,781 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 88 | $14,230 |
| MotegrityPrucalopride Succinate | 11 | $9,190 |
| Mesalamine | 19 | $7,910 |
| Entecavir | 13 | $6,611 |
| Famotidine | 384 | $4,924 |
| Pantoprazole Sodium | 369 | $4,602 |
| Colesevelam Hcl | 48 | $4,600 |
| Colestipol Hcl | 47 | $3,416 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 48 | $3,139 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 24 | $2,867 |
| Budesonide DrBudesonide | 21 | $2,399 |
| Sucralfate | 77 | $1,925 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 112 | $1,768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,619 | $40,42252 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $15,224 | $21,78125 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $55 | $17,097112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $347 | $9,19011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 259 gastroenterology providers in South Carolina.
Other gastroenterology in Charleston
- Erin ForsterCharleston$788K
- Mark DeleggeCharleston$568K
- Nathan ShoresCharleston$217K
- Alejandro SuarezCharleston$210K
- Peter CottonCharleston$193K
- David KochCharleston$48K
- Derek FeussnerCharleston$35K
- Darin DufaultCharleston$33K
- James SchnellCharleston$12K
- Michael SagatelianCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.